Dr. Sia Daneshmand earned his medical degree at the University of California, Davis and completed his residency at the University of Southern California (USC) followed by a two-year fellowship in Urologic Oncology at the USC/Norris Comprehensive Cancer Center. He spent almost 6 years at Oregon Health and Science University where he established the Section of Urologic Oncology as a center of excellence for treatment of bladder and testis cancers. He was recruited to USC Institute of Urology in 2010 as Director of Urologic Oncology. He is currently an associate professor of urology with clinical scholar designation and serves as director of clinical research as well as the urologic oncology fellowship director. Dr. Daneshmand’s main interests include bladder cancer, advanced kidney cancer and testicular cancer. He has extensive experience in urinary diversion and reconstruction following surgical removal of the bladder (radical cystectomy) as well as nerve-sparing retroperitoneal lymph node dissection (RPLND) following chemotherapy for advanced testis cancer. He is one of the highest volume surgeons for this disease on the west coast. He has been selected as one of “True Experts” in the Testicular Cancer Resource Center web site. He also has extensive experience in the management of advanced kidney cancers with vena caval tumor thrombus involvement, as well as prostate cancer, retroperitoneal sarcomas and surgeries requiring replacement of the great vessels. He is a member of Alpha Omega Alpha medical honor society, and has been designated one of the “America’s Top Doctors” for several years. He is an active member of the Society of Urologic Oncology, has presented over 150 abstracts at scientific meetings and has authored over 120 peer-reviewed articles, reviews, and chapters. He is a reviewer for numerous urology journals.